Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxoid targets emerging infectious agent:

This article was originally published in Clinica

Executive Summary

Microbiology diagnostics firm Oxoid has launched a test for nanobacteria, an emerging infectious agent that may be involved with calcification diseases, such as polycystic kidney disease, and may even play a role in some cancers and autoimmune diseases. The Nanocapture ELISA kit detects the nanobacterial antigen in blood or plasma. It is intended for use in research settings and is the only commercially available kit for the agent, the Basingstoke, UK firm claims.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel